Galectin's belapectin shows promise in MASH cirrhosis despite setbacks. High-risk investment with upcoming FDA meeting ...

Analysts have recently evaluated Madrigal Pharmaceuticals and provided 12-month price targets. The average target is $497.5, accompanied by a high estimate of $554.00 and a low estimate of $428.00.

Fact checked by Jennifer Klump Key Takeaways The FDA approved the obesity drug Wegovy as a treatment for people with MASH ...